Sigma-1 targeted PET tracers

Tech ID: T-010394

Technology Description

Researchers at Washington University in St. Louis and their colleagues have developed positron emission tomography (PET) tracers with high affinity for sigma-1 receptors. Sigma receptors have two subtypes, sigma-1 and sigma-2. Sigma-1 has high expression in the limbic and motor structures in the brain. As such, it is an important target for drug development to treat neurological disorders and neuropsychiatric diseases. In addition, imaging sigma-1 receptors in the brain could be used to diagnose disorders of the central nervous system (CNS), monitor disease progression and assess therapeutic efficacy in treating these diseases. PET could be used for such imaging, but sigma-1 specific tracers are lacking. To help meet this need the inventors have developed this technology. It provides compounds that have high affinity and high selectivity for sigma-1 and can used as PET tracers. This technology can be used to diagnose and monitor CNS disorders and serve as a tool to assess treatment efficacy.

Stage of Research

In vivo validation studies using animal models have shown that these compounds can be used as PET radiotracers.

Applications

  • PET imaging for sigma-1 associated conditions, including CNS disorders
    • Track disease progression
    • Assess therapeutic efficacy
  • Potential for therapeutic development

Key Advantages

  • Provides effective sigma-1 targeted PET tracers
  • High affinity for sigma-1
  • High selectivity for sigma-1 versus sigma-2
  • High specific binding of sigma-1 in the brain
  • Good clearance rates from the brain

Publications

Patents

Related Web Links

Create a Collection
Creating...